Sustain
Quality system remediation built to withstand scrutiny
A remediation program is credible only when it addresses systemic causes, protects product while work is underway, and produces evidence that the new controls are effective.
Tailwind helps leadership distinguish completed activity from demonstrated correction, prioritize the work that matters most, and prepare the program for independent or FDA review.
FDA inspection announced — or investigators already on site?
Get inspection help nowA corrective action is only as credible as the evidence demonstrating that the problem was understood and that recurrence has been effectively controlled.
What the engagement includes
- Independent assessment of remediation scope and regulatory significance
- Workstream sequencing, ownership, milestones, and escalation criteria
- Interim-control and product-impact review
- CAPA effectiveness strategy and evidence expectations
- Executive governance and clear compliance-status reporting
- Readiness assessment before certification or reinspection
When teams call
- A remediation program is active but progress is difficult to demonstrate
- CAPAs are closing without persuasive effectiveness evidence
- The same quality-system issues recur across sites or inspections
- Management needs an independent view of true compliance status
- A reinspection or third-party certification is approaching
How we approach it
Define the real system failure
We test whether the program addresses the conditions that allowed the issue—not only the individual event that exposed it.
Prioritize by risk and evidence
Product protection, data reliability, and high-consequence controls come first. Each workstream is tied to evidence a reviewer can test.
Make governance useful
Executives receive a clear view of residual risk, missed milestones, dependencies, and decisions requiring escalation.
Related services
Common questions on timelines, scope, and cost are answered on the FAQ page, and engagement terms are on pricing.
Tailwind Pharma provides independent advisory services and does not replace the manufacturer's designated Quality Unit or guarantee regulatory outcomes.